Mon, Jan 26, 2015, 12:02 AM EST - U.S. Markets open in 9 hrs 28 mins

Recent

% | $
Quotes you view appear here for quick access.

BioLife Solutions, Inc. Message Board

biotechboston 5 posts  |  Last Activity: Jan 21, 2015 9:17 AM Member since: Sep 21, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    what are we missing here ??

    by not.kool Jan 16, 2015 2:11 PM
    biotechboston biotechboston Jan 21, 2015 9:17 AM Flag

    Well come on sellers, get with the program! Can't wait until these days are behind us...all in due time.

    Sentiment: Strong Buy

  • Reply to

    what are we missing here ??

    by not.kool Jan 16, 2015 2:11 PM
    biotechboston biotechboston Jan 21, 2015 6:14 AM Flag

    Serious question--I'm as long on BLFS as one can get, coming from a 30 cent pre-split average to recent purchases at the$2.20-2.30 level. How does a stock run-up on hundreds of thousands of shares volume, and then drop from $2.80-$1.80 on such low volume? Pure supply and demand?

    Sentiment: Strong Buy

  • biotechboston by biotechboston Dec 23, 2014 11:49 AM Flag

    I encourage all current and potential investors to go to the Biolife Solutions website and in the Investors section, read the presentation given at the Dec 3rd Investor Conference. There are 13 Ph3 trials ongoing...each approval will result in $500K to $2M in annual revenue for BLFS. Assuming a 50% success rate for trials in Ph3, that should translate to $6.5M in revenues. There are 60 Ph2 trials-let's assume a 20% success rate, which results in $12M in annual revenues. Then add some placeholder for new trial approvals each year-how about conservatively $4M/new cumulative revenue annually. If you take a 5yr horizon, the clinical trial approvals alone could represent $20M alone and growing.

    Now add in contract mfg and the revenue from product sales and shipping...maybe someone can roughly model that. Again, if I assume 5yr horizon and put a $20M placeholder for these 3 areas (which is conservative), we're looking at $40M in annual revenue. Give it a P/S of your choosing and divide by 12 million shares outstanding. I think a 15 P/S multiple is reasonable for our purposes which is a $50 share price. There's real value here for those willing to invest...

    Sentiment: Strong Buy

  • biotechboston biotechboston Dec 23, 2014 7:26 AM Flag

    And furthermore, this is specifically in reference to the BLFS filing on Nov 6. The confidential treatment is directly linked to the Exhibits details product specs and pricing and technology associated with the SAVSU partnership. Let this be a clear example of the destructive attempts by people such as tomrus to distort the facts and scare investors...for those interested, go to the Biolife website, go to investor section, and click on recent filings. Also, click on the recent investor presentation given on Dec 3rd. This stock is going to mature in 2015 (finally)...we're on the cusp of it being discovered.

    Sentiment: Strong Buy

  • biotechboston biotechboston Dec 23, 2014 7:14 AM Flag

    Plenty of examples where Confidential Treatment order is put into place for competitive reasons. To protect proprietary information or to prevent competitors from understanding pricing of company products--SEC grants this status if it is deemed in the best interest of the company and its investors. If anything, I view this as a potentially positive development of good news on the horizon.

    Sentiment: Strong Buy

BLFS
1.75-0.0600(-3.31%)Jan 23 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.